ValuEngine upgraded shares of Soleno Therapeutics (NASDAQ:SLNO) from a strong sell rating to a sell rating in a research note published on Friday.
Several other research firms also recently commented on SLNO. Maxim Group set a $25.00 price objective on Soleno Therapeutics and gave the company a buy rating in a research note on Thursday, October 12th. reduced their price objective on Soleno Therapeutics from $25.00 to $8.00 and set a buy rating for the company in a research note on Wednesday, November 15th.
Shares of Soleno Therapeutics (SLNO) opened at $1.73 on Friday. The company has a market capitalization of $17.20, a P/E ratio of -1.08 and a beta of 5.52. Soleno Therapeutics has a one year low of $1.32 and a one year high of $4.25.
Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($0.24) EPS for the quarter. Soleno Therapeutics had a negative net margin of 1,389.76% and a negative return on equity of 54.11%.
In other Soleno Therapeutics news, Director Edgar Engleman bought 1,085,480 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was acquired at an average cost of $1.84 per share, with a total value of $1,997,283.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 69.75% of the company’s stock.
A hedge fund recently bought a new stake in Soleno Therapeutics stock. Birchview Capital LP bought a new position in shares of Soleno Therapeutics Inc (NASDAQ:SLNO) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 678,428 shares of the company’s stock, valued at approximately $1,032,000. Soleno Therapeutics makes up 0.6% of Birchview Capital LP’s holdings, making the stock its 14th largest position. Birchview Capital LP owned about 6.78% of Soleno Therapeutics at the end of the most recent reporting period.
ILLEGAL ACTIVITY NOTICE: “Soleno Therapeutics (SLNO) Lifted to Sell at ValuEngine” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/05/soleno-therapeutics-slno-lifted-to-sell-at-valuengine.html.
About Soleno Therapeutics
Soleno Therapeutics, Inc, formerly Capnia, Inc, is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.